The safety and efficacy of bortezomib in relapsed multiple myeloma.
Jagannath
Sundar
S
Multiple Myeloma Service and Bone Marrow and Blood Stem Cell Transplantation Center, Saint Vincent's Comprehensive Cancer Center, New York City, NY, and New York Medical College, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D000069286:Bortezomib; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D012008:Recurrence; D015996:Survival Rate; D016896:Treatment Outcome
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib